Ashwagandha leaf extract: A potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease

被引:94
作者
RajaSankara, Srinivasagam [1 ,2 ]
Manivasagam, Thamilarasan [3 ]
Surendran, Sankar [2 ]
机构
[1] Melmaruvathur Adhi Parasakthi Inst Med Sci, Dept Anat, Melmaruvathur, Tamil Nadu, India
[2] Annamalai Univ, Fac Med, Dept Anat, Annamalainagar 608002, Tamil Nadu, India
[3] Annamalai Univ, Fac Sci, Dept Biochem & Biotechnol, Annamalainagar 608002, Tamil Nadu, India
关键词
Ashwagandha leaf extract; Parkinson's disease; SOD; Catalase; GPx; Glutathione; Oxidative damage; SUPEROXIDE-DISMUTASE ACTIVITY; LIPID-PEROXIDATION; SUBSTANTIA-NIGRA; GLUTATHIONE; NEUROTOXICITY; PATHOGENESIS; ASSAY; MICE;
D O I
10.1016/j.neulet.2009.02.044
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) is a neurodegenerative disorder that leads to impairment of balance and coordination. Therapy for the disease is still under investigation. Withania somnifera (A-Extract), a herbal medicine, has been known for a spectrum of health-promoting effects including activation of immune, muscle and neuronal systems. Therefore effect of A-Extract in the mouse model of PD was examined. The midbrain and corpus striatum of PD mouse showed increased levels of superoxide dismutase, catalase and malondialdehyde; and reduced levels of glutathione and glutathione peroxidase compared to the control. Treatment with A-Extract 100 mg/kg for 7 days significantly improved all these enzyme levels compared to A-Extract untreated PD mouse brain. In the PD mouse grooming, stride length, movement, rearing were found to be decreased compared to the control. In addition, narrow beam walk and foot slippery errors were increased. Treatment with A-Extract improved all these physiological abnormalities. These data suggests that A-Extract is a potential drug in treating oxidative damage and physiological abnormalities seen in the PD mouse, if documented also in patients with PD. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:11 / 15
页数:5
相关论文
共 36 条
  • [1] AEBI H, 1984, METHOD ENZYMOL, V105, P121
  • [2] Oxidative stress on EAAC1 is involved in MPTP-induced glutathione depletion and motor dysfunction
    Aoyama, Koji
    Matsumura, Nobuko
    Watabe, Masahiko
    Nakaki, Toshio
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2008, 27 (01) : 20 - 30
  • [3] Bone K., 1996, MONOGRAPHS W HERBAL, P137
  • [4] Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress
    Chen, XC
    Zhou, YC
    Chen, Y
    Zhu, YG
    Fang, F
    Chen, LM
    [J]. ACTA PHARMACOLOGICA SINICA, 2005, 26 (01) : 56 - 62
  • [5] Genotypic differences in ethanol sensitivity in two tests of motor incoordination
    Crabbe, JC
    Metten, P
    Yu, CH
    Schlumbohm, JP
    Cameron, AJ
    Wahlsten, D
    [J]. JOURNAL OF APPLIED PHYSIOLOGY, 2003, 95 (04) : 1338 - 1351
  • [6] Di Napoli Mario, 2007, Expert Rev Neurother, V7, P1693, DOI 10.1586/14737175.7.12.1693
  • [7] ERIKSEN RL, 2004, DRUG DISCOV TODAY DI, V1, P399
  • [8] A simple method to measure stride length as an index of nigrostriatal dysfunction in mice
    Fernagut, PO
    Diguet, E
    Labattu, B
    Tison, F
    [J]. JOURNAL OF NEUROSCIENCE METHODS, 2002, 113 (02) : 123 - 130
  • [9] MPTP-INDUCED BEHAVIORAL AND BIOCHEMICAL DEFICITS - A PARAMETRIC ANALYSIS
    FREDRIKSSON, A
    ARCHER, T
    [J]. JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1994, 7 (02) : 123 - 132
  • [10] Update on the genetics of Parkinson's disease
    Gasser, Thomas
    [J]. MOVEMENT DISORDERS, 2007, 22 : S343 - S350